
10

20

25

30



whilibh Palant Office

- A method for sequence-based diagnosis of a human neoplastic tissue, blood or other body fluid sample, by analysing from genomic DNA or cDNA derived from said neoplasia the DNA sequence of a gene encoding the cancerrelated p 53 protein for the presence of mutations therein, characterized by a) determining from the presence, nature and location of any such mutation or mutations the influence thereof on the biological function of the corresponding protein and thereby on the properties of the neoplasia, b) classifying the neoplasia into different subgroups depending on (i) the presence or not of a mutation, and (ii) whether the pathent is node positive or not, and on the basis thereof prognosticating the 15 development of the neoplasia and/provide a guidance for adequate treatment of the patient.
 - The method of claim 1, characterized in that said properties of the neoplasia includes biological aggressiveness and/or metastatic potential.
 - The method of claims 1 or 2, characterized by 3. analyzing a part or parts of the gene which encode at least one biologically functional domain of the cancer-related protein.
 - The method ϕ f claim 3, characterized in that said biologically functional domain includes a DNA binding domain and/or transactivation site.

daim 3

- The method of claim 3 or 4, characterized in that evolutionary conserved regions of the gene are analyzed.
- The method of claim 1, characterized in that the neoplasia is/a breast, lung, prostate, gastric, colorectal, 35 melanoma or/leukemia neoplasia.

INVENTA II

24-10-1996

7. The method of claim 6, characterized in that said sample originates from a breast neoplasia.

- The method of claim 7, characterized in that the 8. detection of the presence of a p53 mutation in a node 5 negative patient tumour sample is indiquative of the need of adjuvant therapy following surgical removal of the tumour.
- 9. The method of claim 8, characterized in that the adjuvant therapy is radiation or chemotherapy/hormone 10 therapy. claim 1
- The method of any one of claims 1 to 9, 10. characterized in that it comprises one or more of the following steps: preparation of /genomic DNA or cDNA, 15 amplification of at least part of the cancer-related gene, processing of the cancer-related gene including sequencing reactions, and detection of the products from the sequencing reactions in an automated nucleic acid sequencer, computer software optionally being used to (i) 20 track samples and control process steps and/or (ii) to aid in and/or interpret sequence data obtained.
- A method of dete¢ting mutations in a gene, 11. 25 characterized by comprising the steps of preparing genomic DNA or cDNA, amplifying /at least part of the gene, processing the amplified DNA to produce sequencing reaction products, preferably by solid phase based techniques, detecting the sequencing reaction products in an automated 30 nucleic acid sequencer to determine a DNA sequence or sequences of the p5\$ gene, and comparing the sequence or sequences with the corresponding wild type p53 gene sequence or sequences, computer software being used to (i) track samples and control process steps and/or (ii) to at 35 least aid in interpreting sequence data obtained.

2 4 - 10 - 1996

12. The method according to claim 11, characterized in that mutations are detected in a gene encoding the p53

5

and >